Ascendis Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Tuborg Blvd 12, Hellerup, Region Hovedst...Phone Number
+45 70222244Website
www.ascendispharma.comRevenue
$755.6 MillionStock Symbol
ASNDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
5
1
1
1
1
About Ascendis Pharma
Ascendis Pharma A/S is a global biopharmaceutical company committed to developing innovative therapies that address unmet medical needs and improve patient outcomes. The company leverages its proprietary TransCon® technology platform to develop new, potentially best-in-class treatments with improved safety, efficacy, tolerability, and convenience. Its pipeline includes therapies for rare endocrinology diseases and other serious conditions, with commercial products and candidates advancing in clinical development worldwide. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates internationally, with additional facilities and offices in Europe and the United States.Explore more
Ascendis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascendis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Ascendis Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ascendis Pharma
Funding: Get notified immidiatlly once Ascendis Pharma has new funding data
Earning: See what the market has to say on Ascendis Pharma recently announced quarterly report
Product Launch: Get notified when Ascendis Pharma launches new products
Check out if Ascendis Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Ascendis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ascendis Pharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Ascendis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ascendis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ascendis Pharma.
Ascendis Pharma financials insights
Gather financial insights about Ascendis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$108M
Ascendis Pharma Tech Stack
A closer look at the technologies used by Ascendis Pharma
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Ascendis Pharma News & Media
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment fromPhase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems –5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
– Multi-organ system and quality-of-life benefits sustained through five years of treatmentAscendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy
Ascendis Pharma (NASDAQ:ASND) is one of the most profitable growth stocks to buy. On May 7, Ascendis Pharma reported strong financial results for Q1 2026, reaching a total revenue of €247 million. This growth was primarily driven by YORVIPATH, which generated €197 million, alongside €44 million from SKYTROFA. Additionally, the company announced an agreement to […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ascendis Pharma
Sign Up For FreeTo access detailed company insights
Ascendis Pharma A/S is a global biopharmaceutical company committed to developing innovative therapies that address unmet medical needs and improve patient outcomes. The company leverages its proprietary TransCon® technology platform to develop new, potentially best-in-class treatments with improved safety, efficacy, tolerability, and convenience.... Read More
